BEVERLY HILLS, Calif., March 19, 2014 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc. (OTCQB:RCHA) ("Rich" or the "Company") is pleased to announce the appointment of Dr. McCoy L. Moretz to the Company's Medical Advisory Board.
Dr. Moretz is a board certified surgeon with more than 23 years of experience. He is an internationally renowned cosmetic surgeon and an honors graduate of the Medical College of Georgia. Dr. Moretz completed his surgical internship and residency at Emory University and has operated successful private practices in Atlanta, Georgia and Beverly Hills, California. Board Certified by the ABO, a member of the American Board of Medical Specialties, Dr. Moretz is a Fellow of the American College of Surgeons; American Board of Otolaryngology/Head & Neck Surgery; American Academy of Facial Plastic & Reconstructive surgery; American Academy of Cosmetic Surgery; and American Academy of Otolaryngology/Head & Neck Surgery. Dr. Moretz has joined the Medical Advisory Board to assist the Company with the development and expansion of clinical sites and in the development of protocols.
"We are honored to have Dr. McCoy join our Medical Advisory Board," said Ben Chang, Chief Executive Officer of the Company. "Dr. McCoy's assistance will be invaluable as the Company tracks further into clinical studies. I am delighted to have Dr. McCoy's assistance in our continued endeavors."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (OTCQB:RCHA) is a Biopharmaceutical Company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation and other blood related diseases. Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. Rich Pharmaceuticals' primary development stage product candidate which is known as PD-616 is being designed to treat blood and cancer related diseases through none evasive outpatient facilities. Find out more at www.richpharmaceuticals.com.
Notice Regarding Forward-Looking Statements:
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans, our financial projections or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.
CONTACT: Ben Chang, CEO 9595 Wilshire Blvd., Suite 900 Beverly Hills, CA 90212 424-230-7001 EXT 105Source:Rich Pharmaceuticals, Inc.